logo-loader
viewNovartis AG (ADR)

Adamis Pharmaceuticals shares skyrocket on news of Novartis distribution deal for anaphylaxis product

The deal is with the Sandoz Inc division is for the Adamis’ Symjepi product

1530541374_shutterstock_394493041.jpg
Adamis’ Symjepi product is for the emergency treatment of allergic reactions

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares shot up almost 40% to US$4.45 on Monday after the San Diego-headquartered firm after it announced a distribution and commercialization agreement with drugs giant Novartis Group.

The deal with the latter's Sandoz Inc division is for the  Adamis’ Symjepi product for the emergency treatment of allergic reactions (Type I) including anaphylaxis.

The Symjepi injector is a competitor of Mylan's well-known EpiPen product

Sandoz will distribute and sell the 0.3 and 0.15 mg versions of Symjepi, said Adamis.

"We are very excited about our collaboration with Sandoz," said Dr Dennis J. Carlo, the president and chief executive of Adamis.

"They are among the top pharmaceutical companies in the world and we believe they have the commercial presence and proven track record to maximize the value of Symjepi. 

"We believe the financial terms of this agreement have the potential to bring meaningful recurring revenue to Adamis and we look forward to growing, and possibly expanding, this partnership with Sandoz based on the future success of Symjepi in the market.”

Adamis is a specialty biopharma company, which is focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy.

Quick facts: Novartis AG (ADR)

Price: 92.99 USD

NYSE:NVS
Market: NYSE
Market Cap: $210.59 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Things coming together nicely in Greenland, says Bluejay Mining's CEO

Rod McIllree, Bluejay Mining PLC’s (LON:JAY) chief executive, tells Proactive that all three of its projects in Greenland are shaping up nicely with plenty of interest from mining giants. Dundas is the flagship and here a bulk sample of mineral sands has been shipped to a Rio Tinto facility...

2 days, 12 hours ago

2 min read